Pesquisar um ensaio clínico
Outras opções de pesquisa
56 Resultado(s)
Ensaio em fase de recrutamento = 
; Ensaio a decorrer = 
; Ensaio concluído = 
; Financiado por um membro do IRDiRC = 
; Membro de uma ERN = 
Ensaio (s) clínico (s) nacional (is)
REINO UNIDO
Cambridgeshire
CAMBRIDGE
APRIL: Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease (a feasibility trial)
Addenbrooke's Hospital
Addenbrookes Hospital
REINO UNIDO
Greater London
LONDON
RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
National Heart and Lung Institute, Imperial College, Royal Brompton Campus
Interstitial Lung Disease Unit
SUICA
Suisse Alémanique
ZÜRICH
Prospective Assessment of MRI for Morphological and Functional Imaging in the Thorax
Universitätsspital Zürich
Institut für diagnostische und interventionelle Radiologie
AUSTRIA
WIEN
WIEN
HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD (interstitial lung disease) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Pädiatrische Pulmologie, Allergologie und Endokrinologie
ALEMANHA
Bayern
MÜNCHEN
chILD-EU_EAA: Stop exogenous allergic alveolitis in childhood (StopEAA) - European prospective, multicentre, randomized, double-blind, placebo controlled trial to implement a procedure for everyday care of Exogenous Allergic Alveolitis (Phase II)
Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital
Christiane Herzog Ambulanz
AUSTRIA
WIEN
WIEN
GOOD-IDES: An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Nephrologie und Dialyse
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Service de Pneumologie
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service de pneumologie
ALEMANHA
Nordrhein-Westfalen
MÜNSTER
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study - DE
Universitätsklinikum Münster
Centrum für seltene Erkrankungen (ZSE) Münster
AUSTRALIA
Victoria
ADDRESS: NOT PROVIDED - AU
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -AU
Institution: Information not provided - AU
AUSTRIA
STEIERMARK
GRAZ
ANCA_CGM: Influence of once vs twice daily corticosteroid administration on glycemia assessed by continuous glucose monitoring in patients with ANCA vasculitis (phase 4)
Medizinische Universität Graz
Klinische Abteilung für Nephrologie
BULGARIA
South-West region
SOFIA
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - BG -
University Hospital Alexandrovska
Clinic of Hematology
ESLOVAQUIA
Bratislavsky kraj
ADDRESS: NOT PROVIDED - SK
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -SK
Institution: Information not provided - SK
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
ELIKIDS: Open label, Two Cohort (with and without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients with Gaucher Disease Type 1 and Type 3 -ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
TransportNPC: A Phase 3, Double blind, Randomized, Placebo controlled, Parallel group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol Cyclo (Hydroxypropyl beta cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann Pick Disease Type C1 -ES
Institution: Information not provided - ES
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1): Potential Use of Antioxidant/Anti-inflammatory Medications
Institution: Information not provided - US
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
MASTER-ANCA: Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial.
Institution: Information not provided - FR
FRANCA
ILE-DE-FRANCE
PARIS
PEXIVAS: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis. An International Randomised Controlled Trial (phase III) - FR
AP-HP.Centre - Université de Paris - Hôpital Cochin
Unité fonctionnelle de Médecine interne et centre de référence maladies rares
ISRAEL
ISRAEL
PETAH TIKVA
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - IL -
Rabin Medical Center - Beilinson Hospital
Recanati Genetic Institute
ITALIA
CAMPANIA
NAPOLI
Efficacy and safety of treatment with miglustat in patients with Niemann-Pick disease type c
Azienda Ospedaliera Universitaria "Federico II"
Laboratorio Dipartimento di Pediatria
ITALIA
FRIULI VENEZIA GIULIA
UDINE
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - IT -
Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine
Centro di Coordinamento Regionale per le Malattie Rare
ITALIA
PUGLIA
BARI
Combined Therapy With Peg-Interferon alpha, Ribavirin And Rituximab Of Hepatitis C Virus-Related Mixed Cryoglobulinemia - IT
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Unità di Epatologia - Sezione di Medicina Interna e Oncologia Clinica
LIBANO
Beyrouth
BEIRUT
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - LB -
Hôtel-Dieu de France, Université Saint-Joseph
Oncology & Hematology
REINO UNIDO
Cambridgeshire
CAMBRIDGE
Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS
Addenbrooke's Hospital
Addenbrookes Hospital
REINO UNIDO
Greater London
ADDRESS: NOT PROVIDED - GB
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -GB
Institution: Information not provided - GB
REINO UNIDO
Greater London
LONDON
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis-GB
Imperial College London, main campus
Imperial College London Headquarters
REINO UNIDO
Greater London
LONDON
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis-GB
Imperial College NHS Trust
REPUBLICA CHECA
Capital City Prague
PRAHA
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - CZ -
Vseobecna fakultni nemocnice a 1. lekarska fakulta UK
National Centre for Treatment of Gaucher Disease
SUICA
Suisse Alémanique
BERN
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study - CH
Universitätsspital Inselspital
University Hospital Inselspital
TUNISIA
TUNISIA
TUNIS
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - TN -
Hôpital La Rabta
Service de Pédiatrie
TURQUIA
TURKEY
IZMIR
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - TR -
Ege Üniversitesi
Department of Pediatrics - Cocuk asgligi ve Hastaliklari Anabilim Dali
ALEMANHA
Baden-Württemberg
MANNHEIM
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsmedizin Mannheim
Universitätsklinikum Mannheim
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) -DE-
Institution: Information not provided - DE
ALEMANHA
Berlin
BERLIN
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Charité - Universitätsmedizin Berlin
ALEMANHA
Nordrhein-Westfalen
ESSEN
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsklinikum Essen
ALEMANHA
Nordrhein-Westfalen
MÜNSTER
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsklinikum Münster
ALEMANHA
Sachsen
DRESDEN
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
ALEMANHA
Thüringen
JENA
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsklinikum Jena
ESPANHA
Cataluña
BARCELONA
ABROGATE: Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non Severe, Granulomatosis with Polyangiitis (Wegener's) - ES
Hospital Clínic de Barcelona
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
OCEAN: A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy -ES
Institution: Information not provided - ES
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Phase 1/2a Study of 2-Hydroxypropyl-Beta-Cyclodextrin Therapy for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
Institution: Information not provided - US
FRANCA
AUVERGNE-RHONE-ALPES
PIERRE-BENITE
MAINEPSAN Study: A Prospective Comparative Randomized Double-blind Placebo-controlled In-Parallel Groups Multicenter, Study to Evaluate the remission MAINtenance using Extended administration of Prednisone in Systemic anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis
CHU de Lyon HCL - GH Sud
Service de médecine interne et pathologie vasculaire
FRANCA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) - FR
Institution: Information not provided - FR
FRANCA
ILE-DE-FRANCE
PARIS
CHUSPAN2 : Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Churg Strauss Syndrome Without Poor Prognosis Factors (Phase III)
AP-HP.Centre - Université de Paris - Hôpital Cochin
Unité fonctionnelle de Médecine interne et centre de référence maladies rares
PAISES BAIXOS
Groningen
GRONINGEN
Prevention of Relapses in Proteinase 3 (PR3)-Anti-Neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
UMCG - Universitair Medisch Centrum Groningen
Afdeling Nefrologie
Ensaio (s) clínico (s) multinacional (ais)
CANADA
Alberta
MOUNTAIN VIEW
ESTADOS UNIDOS
Massachusetts
CAMBRIDGE
ESTADOS UNIDOS
Pennsylvania
PHILADELPHIA
PEXIVAS: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial (phase III) (coordination)
Hospital of the University of Pennsylvania
Rheumatology Division
PAISES BAIXOS
Utrecht
ADDRESS: NOT PROVIDED - NL
A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease (Phase III) (Coordination)
Institution: Information not provided - NL
PAISES BAIXOS
Utrecht
ADDRESS: NOT PROVIDED - NL
EDGE: A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once Daily versus Twice Daily Dosing of Genz-112638 in Patients with Gaucher Disease Type 1 who have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Institution: Information not provided - NL
PAISES BAIXOS
Zuid-Holland
LEIDEN
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis
LUMC - Leids Universitair Medisch Centrum
REINO UNIDO
Greater London
ADDRESS: NOT PROVIDED - GB
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study
Institution: Information not provided - GB
REINO UNIDO
Oxfordshire
BEGBROKE
REINO UNIDO
Greater London
ADDRESS: NOT PROVIDED - GB
A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy (Phase III)
Institution: Information not provided - GB
REINO UNIDO
Greater London
ADDRESS: NOT PROVIDED - GB
Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy)
Institution: Information not provided - GB
SUICA
Suisse Romande
ADDRESS: NOT PROVIDED - CH